3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
13
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
150
Colorectal Neoplasms
82
Stomach Neoplasms
77
Neoplasms
35
Neoplasm Metastasis
35
Pancreatic Neoplasms
25
Triple Negative Breast Neoplasms
22
Parkinson Disease 4, Autosomal Dominant Lewy Body
16
Adenocarcinoma
13
Esophageal Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colonic Neoplasms
10
Biliary Tract Neoplasms
10
Rectal Neoplasms
9
Carcinoma, Hepatocellular
9
Brain Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Adenocarcinoma Of Esophagus
7
Solid Tumor
6
Ovarian Neoplasms
6
Cholangiocarcinoma
6
Nasopharyngeal Carcinoma
5
Gastrointestinal Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Recurrence
4
Nasopharyngeal Neoplasms
4
Advanced Solid Tumors
4
Sarcoma
3
Melanoma
3
Head and Neck Neoplasms
3
Interventions
aflibercept
6
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Fluorouracil
2
Capecitabine
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
raltitrexed
1
monoclonal antibody YYB-101
1
masitinib
1
atezolizumab
1
Vemurafenib
1
Panitumumab
1
Nivolumab
1
IFL protocol
1
HMPL-013
1
Ethiodized Oil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colorectal Cancer Metastatic
×
Capecitabine
×
Clear all
NCT01955629
2016-04-18
AMOR
Sanofi
Phase 1/2
Terminated
4 enrolled
7 charts
NCT02085005
2014-11-18
Drop and Go
Sanofi
Phase 2
Withdrawn